The insulin/IGF system in colorectal cancer development and resistance to therapy

164Citations
Citations of this article
149Readers
Mendeley users who have this article in their library.

Abstract

The insulin/insulin-like growth factor (IGF) system is a major determinant in the pathogenesis and progression of colorectal cancer (CRC). Indeed, several components of this signaling network, including insulin, IGF-1, IGF-2, the IGF-binding proteins, the insulin receptor (IR), the IGF-1 receptor (IGF-1R), and IR substrate proteins 1 and 2 contribute to the transformation of normal colon epithelial cells. Moreover, the insulin/IGF system is also implicated in the development of resistance to both chemotherapeutic drugs and epidermal growth factor receptor targeted agents. The identification of hybrid receptors comprising both the IR and IGF-1R adds further complexity to this signaling network. Thus, a comprehensive understanding of the biological functions performed by each component of the insulin/IGF system is required to design successful drugs for the treatment of CRC patients.

Cite

CITATION STYLE

APA

Vigneri, P. G., Tirrò, E., Pennisi, M. S., Massimino, M., Stella, S., Romano, C., & Manzella, L. (2017, January 1). The insulin/IGF system in colorectal cancer development and resistance to therapy. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2015.00230

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free